Bodurtha Smith Anna Jo, Fader Amanda Nickles, Tanner Edward J
Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, Baltimore, MD.
Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, Baltimore, MD.
Am J Obstet Gynecol. 2017 May;216(5):459-476.e10. doi: 10.1016/j.ajog.2016.11.1033. Epub 2016 Nov 18.
BACKGROUND: In the staging of endometrial cancer, controversy remains regarding the role of sentinel lymph node mapping compared with other nodal assessment strategies. OBJECTIVE: We conducted a systematic review to evaluate the diagnostic accuracy and clinical impact of sentinel lymph node mapping in the management of endometrial cancer. DATA SOURCES: We searched Medline, Embase, and the Cochrane Central Registry of Controlled trials for studies published in English before March 25, 2016 (PROSPERO CRD42016036503). STUDY ELIGIBILITY CRITERIA: Studies were included if they contained 10 or more women with endometrial cancer and reported on the detection rate, sensitivity, and/or impact on treatment or survival of sentinel lymph node mapping. STUDY APPRAISAL AND SYNTHESIS METHODS: Two authors independently reviewed abstracts and full-text articles for inclusion and assessed study quality. The detection rate, sensitivity, and factors associated with successful mapping (study size, body mass index, tumor histology and grade, injection site, dye type) were synthesized through random-effects meta-analyses and meta-regression. RESULTS: We identified 55 eligible studies, which included 4915 women. The overall detection rate of sentinel lymph node mapping was 81% (95% confidence interval, 77-84) with a 50% (95% confidence interval, 44-56) bilateral pelvic node detection rate and 17% (95% confidence interval, 11-23) paraaortic detection rate. There was no difference in detection rates by patient body mass index or tumor histology and grade. Use of indocyanine green increased the bilateral detection rate compared with blue dye. Additionally, cervical injection increased the bilateral sentinel lymph node detection rate but decreased the paraaortic detection rate compared with alternative injection techniques. Intraoperative sentinel lymph node frozen section increased the overall and bilateral detection rates. The sensitivity of sentinel node mapping to detect metastases was 96% (95% confidence interval, 91-98); ultrastaging did not improve sensitivity. Compared with women staged with complete lymphadenectomy, women staged with sentinel lymph node mapping were more likely to receive adjuvant treatment. CONCLUSION: Sentinel lymph node mapping is feasible and accurately predicts nodal status in women with endometrial cancer. The current data favors the use of cervical injection techniques with indocyanine green. Sentinel lymph mapping may be considered an alternative standard of care in the staging of women with endometrial cancer.
背景:在子宫内膜癌的分期中,与其他淋巴结评估策略相比,前哨淋巴结定位的作用仍存在争议。 目的:我们进行了一项系统评价,以评估前哨淋巴结定位在子宫内膜癌管理中的诊断准确性和临床影响。 数据来源:我们检索了Medline、Embase和Cochrane对照试验中央注册库,以获取2016年3月25日前发表的英文研究(PROSPERO CRD42016036503)。 研究纳入标准:如果研究纳入了10名或更多子宫内膜癌女性,并报告了前哨淋巴结定位的检出率、敏感性和/或对治疗或生存的影响,则纳入该研究。 研究评估与综合方法:两位作者独立审查摘要和全文文章以确定是否纳入,并评估研究质量。通过随机效应荟萃分析和荟萃回归综合分析了检出率、敏感性以及与成功定位相关的因素(研究规模、体重指数、肿瘤组织学和分级、注射部位、染料类型)。 结果:我们确定了55项符合条件的研究,共纳入4915名女性。前哨淋巴结定位的总体检出率为81%(95%置信区间,77 - 84),双侧盆腔淋巴结检出率为50%(95%置信区间,44 - 56),腹主动脉旁检出率为17%(95%置信区间,11 - 23)。患者体重指数、肿瘤组织学和分级对检出率无差异。与蓝色染料相比,使用吲哚菁绿可提高双侧检出率。此外,与其他注射技术相比,宫颈注射可提高双侧前哨淋巴结检出率,但会降低腹主动脉旁检出率。术中前哨淋巴结冰冻切片可提高总体和双侧检出率。前哨淋巴结定位检测转移的敏感性为96%(95%置信区间,91 - 98);超分期并未提高敏感性。与接受完整淋巴结清扫术分期的女性相比,接受前哨淋巴结定位分期的女性更有可能接受辅助治疗。 结论:前哨淋巴结定位在子宫内膜癌女性中是可行的,并且能够准确预测淋巴结状态。目前的数据支持使用吲哚菁绿的宫颈注射技术。前哨淋巴结定位可被视为子宫内膜癌女性分期的一种替代标准治疗方法。
Am J Obstet Gynecol. 2017-5
Minerva Ginecol. 2018-4
Cochrane Database Syst Rev. 2017-10-2
Int J Gynecol Cancer. 2025-6
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2018-5-15
Scientifica (Cairo). 2025-7-7
Int J Gynaecol Obstet. 2025-9
Cochrane Database Syst Rev. 2025-6-10
J Clin Med. 2025-1-21